Orchid Pharma524372Board meeting scheduled

Board meeting on October 20, 2026 to consider and evaluate options for raising funds

Orchid Pharma has informed the exchanges that its Board of Directors will meet on Tuesday, October 20, 2026.

By ScoutQuest · Thu 15 Oct 2026, 8:14 PM IST · 2 min read

Board Meeting Date: Tuesday, October 20, 2026
Intimation Date: October 15, 2026
Stated Purpose: to consider and evaluate various options for raising funds

What the company has told the exchanges

Orchid Pharma has intimated that a meeting of its Board of Directors is scheduled to be held on Tuesday, October 20, 2026. The stated purpose is to consider and evaluate various options for raising funds.

What the board will consider

Issue of equity shares or any other eligible securities or instruments.
Fully or partly convertible debentures.
A composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares or other eligible securities.
Routes named: qualified institutions placement, preferential issue, private placement, public issue of equity shares and/or debt securities, or through any other permissible mode.
Any combination of the above, as may be considered appropriate.

What this update is

This is a prior intimation of a board meeting. The board is to consider and evaluate the options for raising funds. The intimation is dated October 15, 2026, and the meeting is scheduled for October 20, 2026.

Approvals involved

The update states that any such move would be subject to such statutory and regulatory approvals as may be required, including the approval of the members of the Company, wherever applicable, and such other approvals, permissions and consents as may be necessary.

Why a retail investor may note this

A fund raise through equity shares or convertible instruments can change the number of shares in issue, which affects the stake held by existing shareholders.
A fund raise through debt or non-convertible debentures relates to borrowings and the obligations that come with them.
These are options placed before the board to consider and evaluate; the route, size, price and timing are for the board to decide, subject to the approvals mentioned above.

Simple summary

The company has informed the exchanges that its board will meet on October 20, 2026 to consider and evaluate ways of raising funds, across equity, convertible and debt instruments and combinations of them, through routes such as qualified institutions placement, preferential issue, private placement or a public issue. Any decision would follow the required approvals, including members' approval wherever applicable.

Also from Orchid Pharma